---
title: "Enhancing Cognitive Processing Therapy for Posttraumatic Stress Disorder Via Stellate Ganglion Block Treatment: A Pilot Trial"
nct_id: NCT05534126
overall_status: COMPLETED
phase: NA
sponsor: Rush University Medical Center
study_type: INTERVENTIONAL
primary_condition: Posttraumatic Stress Disorder
countries: United States
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT05534126.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT05534126"
ct_last_update_post_date: 2025-10-24
last_seen_at: "2026-05-12T07:33:06.813Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Enhancing Cognitive Processing Therapy for Posttraumatic Stress Disorder Via Stellate Ganglion Block Treatment: A Pilot Trial

**NCT ID:** [NCT05534126](https://clinicaltrials.gov/study/NCT05534126)

## Key Facts

- **Status:** COMPLETED
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 60
- **Lead Sponsor:** Rush University Medical Center
- **Conditions:** Posttraumatic Stress Disorder, Chronic Pain
- **Start Date:** 2022-11-01
- **Completion Date:** 2025-09-30
- **CT.gov Last Update:** 2025-10-24

## Brief Summary

Cognitive Processing Therapy (CPT) is an effective first-line, evidence-based treatment for posttraumatic stress disorder (PTSD). Despite its well-demonstrated effectiveness, research has shown that approximately two-thirds of individuals continue to meet the diagnostic criteria for PTSD even after successful treatment completion. Stellate Ganglion Block (SGB) treatment, involving a local anesthesia injection to the stellate ganglion (around the lower base of the neck), has been shown to block its pain signal transmissions. Prior case studies and reviews have provided evidence for reducing PTSD symptoms with SGB treatment. However, studies to date have only examined SGB as a standalone intervention. The utility of combining CPT with concurrent SGB treatment remains unknown, although it is plausible that the combination of the two treatments can improve the effectiveness of CPT alone. The present study aims to test this hypothesis by comparing either a combined 1-week massed CPT + SGB treatment and 1-week massed CPT + placebo treatment (saline injection) using a randomized controlled trial design.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** Yes

```
Inclusion Criteria:

1. Are 18 years or older
2. Are fluent in English
3. Reside in Illinois
4. Have safe transportation means other than driving themselves to Rush University Medical Center for two separate procedures (e.g., Uber, family or friend to drive them to study visits, etc.)
5. Have experienced a Criterion A traumatic event during their lifetime
6. Have a PTSD diagnosis verified via the Clinician Administered PTSD Scale for DSM-5
7. Have not previously received stellate ganglion blocks
8. Are willing and able to participate in daily Cognitive Processing Therapy over the course of one week
9. Are willing and able to complete self-report measures and clinician-rated assessments at multiple time points over the course of the study

Exclusion Criteria:

1. The traumatic event occurred in the past month
2. They are currently suicidal or homicidal (i.e., plan and intent)
3. They have unmanaged psychosis or mania
4. They have not been on a stable dose of psychotropic medication for at least one month by the time of the baseline assessment or are planning to change their medications within 3 months of starting their participation in the study
5. They have completed an evidence-based cognitive behavioral PTSD treatment (e.g., Cognitive Processing Therapy or Prolonged Exposure) in the past 12 months or are currently receiving an evidence-based PTSD treatment
6. They have an intellectual disability or significant cognitive impairment that would prevent them from engaging in CPT, as assessed via the Mini-Mental State Exam-Second Edition (MMSE-2)
7. They are currently on any blood-thinning medications or have a coagulopathy
8. They have any of the following conditions: a recent myocardial infarction, glaucoma, a pre-existing contralateral nerve palsy, severe emphysema or a cardiac conduction blockade.
9. They are allergic to any of the medications injected (i.e., ropivacaine, lidocaine, propofol, medications)
10. They have an active infection
11. They have a serious or unstable medical illness or instability for which hospitalization may be likely within the next year
12. They have a visual or auditory impairment that would prevent them from fully participating in study activities
13. They are involved with current legal actions related to the traumatic event that is anticipated to be targeted during treatment
14. Subjects who, at the time of consent, appear to have extenuating life circumstances (e.g., unstable housing, no internet access, etc.) which, in the judgement of the Principal Investigator, could affect the ability to deliver the intervention with fidelity
```

## Arms

- **Stellate Ganglion Block** (ACTIVE_COMPARATOR)
- **Placebo** (PLACEBO_COMPARATOR)

## Interventions

- **Stellate Ganglion Block Treatment** (PROCEDURE) — Stellate ganglion block procedure is a treatment that involves injection of local anesthetic around the stellate ganglion (located at the base of the neck) to block its transmission of pain signals.
- **Placebo** (PROCEDURE) — Sham

## Primary Outcomes

- **Clinician Administered PTSD Scale for DSM-5** _(time frame: Through study completion, on average of 3 months)_ — Clinician Administered Assessment of PTSD
- **PTSD Checklist for DSM-5 Criteria** _(time frame: Through study completion, on average of 3 months)_ — Self-report measure for PTSD

## Locations (1)

- Rush University Medical Center, Chicago, Illinois, United States

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.rush university medical center|chicago|illinois|united states` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT05534126.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT05534126*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*